The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes

References

• Silverman LR. The myelodysplastic syndrome. In: Kufe D, Frei EI, Holland J, et al., editors. Cancer medicine. 8th ed. Shelton (CT): People’s Medical Publishing House; 2009. p. 1544–1558.
   Google Scholar
• Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol. 2004;41(4):6–12.
   PubMed Web of Science ®Google Scholar
• Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10(3):272–281.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, Lebeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009;15(2):137–172.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011;29(5):516–523.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Ades L. Review of azacitidine trials in intermediate-2 and high-risk myelodysplastic syndromes. Leuk Res. 2009;33(Suppl 2):S7–S11.
   Google Scholar
• Kantarjian HM, O’Brien S, Shan J, et al. Update of the decitabine experience in higher-risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109(2):265–273.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987–1996.
   PubMed Web of Science ®Google Scholar
• Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–3327.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830–3834.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Greenberg P, Raza A, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2015;33:57–66.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomized, controlled, phase 3 trial. Lancet Oncol. 2016;17(4):496–508.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49(4):690–695.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Apuri S, Ali N, et al. Evidence for selective benefit of sequential treatment with azanucleosides in patients with myelodysplastic syndromes (MDS). ASCO Meet Abstr. 2013;31(15 Suppl):7113.
   Google Scholar
• Komrokji RS. Treatment of higher-risk myelodysplastic syndromes after failure of hypomethylating agents. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S56–S59.
   PubMed Web of Science ®Google Scholar
• Reddy MV, Venkatapuram P, Mallireddigari MR, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2ʹ,4ʹ,6ʹ-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem. 2011;54(18):6254–6276.
   PubMed Web of Science ®Google Scholar
• Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, et al. A small molecule Ras-mimetic disrupts Ras association with effector proteins to block signaling. Cell. 2016;165(3):643–655.
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Reddy MV, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005;7(3):275–286.
   PubMed Web of Science ®Google Scholar
• Hyoda T, Tsujioka T, Nakahara T, et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci. 2015;106(3):287–293.
   PubMed Web of Science ®Google Scholar
• Prasad A, Park I-W, Allen H, et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene. 2009;28(12):1518–1528.
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Shenoy A, Weinstein B, et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with 01910.Na. Leuk Res. 2012;36(8):982–989.
   PubMed Web of Science ®Google Scholar
• Chun AW, Cosenza SC, Taft DR, et al. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol. 2009;65:177–186.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Raza A, Lancet JE, et al. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol. 2013;162(4):517–524.
   PubMed Web of Science ®Google Scholar
• Seetharam M, Fan AC, Tran M, et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012;36(1):98–103.
   PubMed Web of Science ®Google Scholar
• Raza A, Tycko B, Lin S, et al. Oral rigosertib (ON 01910.Na) treatment produces an encouraging rate of transfusion independence in lower risk myelodysplastic syndromes (MDS) patients; a genomic methylation profile is associated with responses. Blood. 2013;122(21):2745.
   Web of Science ®Google Scholar
• Skiddan I, Zinzar S, Holland JF, et al. Toxicology of a small molecule ON1910Na on human bone marrow and leukemic cells in vitro. Am Assoc Cancer Res Abstr. 2006;1310(47):309.
   Google Scholar
• Navada SC, Garcia-Manero G, Hearn KP, et al. Results from phase I/II study of the combination of oral rigosertib and azacitidine in patients with myelodysplastic syndromes (MDS). 21st Congress of the European Hematology Association (EHA). Abstract P256;; 2016.
   Google Scholar